Provided by Tiger Trade Technology Pte. Ltd.

Biomea Fusion, Inc.

1.70
-0.1450-7.86%
Post-market: 1.700.00000.00%16:00 EDT
Volume:2.46M
Turnover:4.26M
Market Cap:122.91M
PE:-3.61
High:1.84
Open:1.83
Low:1.68
Close:1.85
52wk High:2.99
52wk Low:0.8719
Shares:72.30M
Float Shares:67.01M
Volume Ratio:1.07
T/O Rate:3.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4711
EPS(LYR):-1.1832
ROE:-164.14%
ROA:-63.46%
PB:10.13
PE(LYR):-1.44

Loading ...

Biomea Fusion reports Q2 EPS (12c), consensus (23c)

TIPRANKS
·
Aug 06

Biomea Fusion Q2 Loss Narrows, Cash Runway into Q2 2027

Reuters
·
Aug 06

Biomea Fusion Q2 Net Loss Narrows to $8.33 Million; R&D Expenses Fall 44.68% to $9.14 Million

Reuters
·
Aug 06

Biomea Fusion Q2 Basic EPS USD -0.12

THOMSON REUTERS
·
Aug 06

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

GlobeNewswire
·
Aug 06

Biomea Fusion Inc Expected to Post a Loss of 22 Cents a Share - Earnings Preview

Reuters
·
Aug 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 31

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)

TIPRANKS
·
Jun 24

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)

TIPRANKS
·
Jun 12

Biomea Fusion shareholders elect two directors at annual meeting

Reuters
·
Jun 11

Biomea Labs: Buy Rating Reiterated as Icovamenib Data Strengthen Metabolic Disease Thesis; $4 Price Target Maintained

TIPRANKS
·
Jun 08

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“Ada”) 86TH Scientific Sessions and Announces Expansion of Ongoing Phase I Bmf-650 Study

THOMSON REUTERS
·
Jun 06

Biomea Fusion - Icovamenib Data Show Muscle Preservation and Fat Reduction in Obesity and Diabetes

THOMSON REUTERS
·
Jun 06

Biomea Fusion - Icovamenib Improves Hba1c and C-Peptide in Type 1 Diabetes With No Immune Activation

THOMSON REUTERS
·
Jun 06

Biomea Fusion: Expanded Phase I Bmf-650 Study to Evaluate a Rapid One-Step Titration, Enhanced Weight Loss Potential With Oral Glp-1 Receptor Agonist

THOMSON REUTERS
·
Jun 06

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

GlobeNewswire
·
Jun 06

Biomea Fusion management to meet with Citizens

TIPRANKS
·
Jun 05

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Jun 03

Biomea Fusion, University of Leicester to study icovamenib plus semaglutide in obesity trial

Reuters
·
Jun 03

Biomea Fusion - Study to Evaluate Icovamenib With Semaglutide for Enhanced Weight Loss

THOMSON REUTERS
·
Jun 03